Invitrogen has extended its open architecture licensing framework to its GeneBLAzer cell-based assay reporter system and Voltage Sensor Probe technology for ion channel screening. With the GeneBLAzer and Voltage Sensor Probe open architecture business model, researchers can purchase the technologies outside of the restrictive licensing relationships that comprised the former business model. The GeneBLAzer cell-based beta-lactamase (BLA) system combines traditional molecular and cellular biology with a Fluorescence Resonance Energy Transfer (FRET)-based detection method to conduct high-throughput screening experiments. This method enables drug discovery scientists to accurately measure functional cellular responses related to specific drug targets, in living cells and in very miniature formats. Voltage Sensor Probe technology for ion channel screening also utilizes a FRET-based detection method that provides ratiometric results, significantly reducing errors arising from well-to-well variations in cell number, dye loading and signal intensities, plate inconsistencies, and temperature fluctuations. Both technologies are now available as a linked set of "off-the-shelf" tools and solutions. The GeneBLAzer system is offered as: validated, cell-based assays for nuclear receptors and GPCRs; master cell lines and vectors for flexible, assay development; and substrate loading kits. Evaluation kits, complete with a detailed product protocol, are also available for the Voltage Sensor Probe technology, in addition to the traditional bulk sizes already utilized by multiple high-throughput screening labs.